

Cenicriviroc Mesylate

Catalog No: tcsc0032631

Available Sizes

Size: 1mg			
Size: 5mg			
Size: 10mg			
Size: 25mg			
Size: 50mg			
Specifications			

CAS No: 497223-28-6

Formula:

 $C_{42}H_{56}N_4O_7S_2$

Pathway: Immunology/Inflammation;GPCR/G Protein;Anti-infection

Target: CCR;CCR;HIV

Purity / Grade:

>98%

Solubility: DMSO : ≥ 107.5 mg/mL (135.55 mM)

Alternative Names:

TAK-652 Mesylate; TBR-652 Mesylate

Copyright 2021 Taiclone Biotech Corp.



Observed Molecular Weight:

793.05

Product Description

Cenicriviroc is a dual **CCR2/CCR5** antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.

IC50 & Target: CCR2/CCR5^[1]

In Vitro: Migration of mouse monocytes in response to carbon tetrachloride (CCL2) is reduced following pre-treatment with Cenicriviroc Mesylate (CVC) at a concentration of 1 μ M. Compare to untreated and unstimulated cells, the average fold change in migrating cells (±SD) is 0.8±0.2 (p>0.05) and 0.7±0.4 (p>0.05) for CCL2-stimulated cells treated with Cenicriviroc Mesylate and unstimulated cells treated with Cenicriviroc Mesylate, respectively^[1]. Phenotypic susceptibility testing shows, for the four R5-tropic HIV-2 isolates, a median EC₅₀ for Cenicriviroc Mesylate of 0.39 nM (0.03, 0.33, 0.45 and 0.98 nM). The dual-tropic and the X4-tropic HIV-2 strains are resistant to Cenicriviroc Mesylate with EC₅₀ at >1000 nM, and Maximum percentages of inhibition (MPI) at 33% and 4%, respectively^[2].

In Vivo: Cenicriviroc Mesylate (CVC) treatment leads to dose-related decrease in monocyte/macrophage recruitment, of similar or greater magnitude than those observed with dexamethasone (positive control), and achieving statistical significance at doses \geq 20 mg/kg/day (p[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.